Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Urabe F; Suzuki H; Iwatani K; Kimura T

doi:10.1111/iju.15537

Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Affiliations

1. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Authors
Urabe F¹
Suzuki H¹
Iwatani K¹
Kimura T¹
(4 authors)

ORCIDs linked to this article

International Journal of Urology : Official Journal of the Japanese Urological Association, 16 Jul 2024, 31(10):1107
https://doi.org/10.1111/iju.15537 PMID: 39010790

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1111/iju.15537

Similar Articles

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
Kikuchi E, Hayakawa N
Int J Urol, 31(10):1106, 16 Jul 2024
Cited by: 0 articles | PMID: 39010787
Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Hattori Y, Fujiwara T, Hagimoto H, Kokubun H, Murata S, Makita N, Abe Y, Kubota M, Tohi Y, Tsutsumi N, Shibasaki N, Inoue K, Kawakita M, Yamasaki T
Int J Urol, 31(10):1102-1106, 03 Jul 2024
Cited by: 0 articles | PMID: 38961545
Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
Mitsui Y, Okawa M, Hori S, Uetani M, Kasahara M, Yamabe F, Kobayashi H, Nagao K, Nakajima K
Int J Urol, 31(9):1030-1037, 31 May 2024
Cited by: 0 articles | PMID: 38819073
Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW
Urology, 188:118-124, 28 Apr 2024
Cited by: 0 articles | PMID: 38685388 | PMCID: PMC11460315
Review Free full text in Europe PMC

Search life-sciences literature (45,104,931 articles, preprints and more)

Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

Similar Articles

Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.

Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.

Partnerships & funding

Search life-sciences literature (45,104,931 articles, preprints and more)

Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Author information

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

Similar Articles

Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".

Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.

Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.

Partnerships & funding